Jiangsu Aidea Pharmaceutical announced that the company proactively applied to withdraw the application for the new indication of Aino Wei Lin tablets, and has obtained approval from the National Medical Products Administration. As of the date of the announcement, the application for the new indication of Aino Mitie tablets, a single tablet compound formulation containing Aino Wei Lin ingredients, is progressing smoothly and is currently undergoing document preparation and review and approval. The company will continue to actively promote the listing of Aino Mitie tablets and closely follow the approval status.